undamentalytics Newsletter
Sign in

Lilly (Eli) number of employees

Lilly (Eli) reported 50,000 employees at December 31, 2025 in its latest annual report, up 3,000 (6.4%) on the year before. That compares with 35,000 at December 31, 2021. Revenue per employee was $1.3m.

Headcount by year

Fiscal year endEmployeesChangeRevenue per employeeSource
December 31, 2025 50,000 +3,000 (6.4%) $1.3m 10-K, filed February 12, 2026
December 31, 2024 47,000 +4,000 (9.3%) $958,362 10-K, filed February 19, 2025
December 31, 2023 43,000 +4,000 (10.3%) $793,581 10-K, filed February 21, 2024
December 31, 2022 39,000 +4,000 (11.4%) $731,831 10-K, filed February 22, 2023
December 31, 2021 35,000 — $809,097 10-K, filed February 23, 2022

What the annual reports say

  • At the end of 2025, we employed approximately 50,000 people, including approximately 27,000 employees outside the U.S. 2025 annual report
  • At the end of 2024, we employed approximately 47,000 people, including approximately 25,000 employees outside the U.S. 2024 annual report
  • At the end of 2023, we employed approximately 43,000 people, including approximately 23,000 employees outside the U.S. 2023 annual report
  • At the end of 2022, we employed approximately 39,000 people, including approximately 21,000 employees outside the U.S. 2022 annual report
  • At the end of 2021, we employed approximately 35,000 people, including approximately 19,600 employees outside the U.S. 2021 annual report

Headcount as the company states it in Item 1 of its annual report (some count full-time equivalents or exclude part-time and temporary staff), at the date it gives. Years where the report states no clear total are left out rather than estimated. Changes can reflect acquisitions and disposals as well as hiring and job cuts.

Compare with peers

Head to head: JNJ vs LLYLLY vs PFE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Lilly (Eli)'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lilly (Eli).